Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, we are developing small molecule drug candidates specifically engineered to impact muscle function and contractility. 

Proud to be a San Francisco Business Times Best Place to Work in 2021 and 2022, a Great Place to Work-Certified company in 2022 and a part of Fortune's Best Workplaces in the Bay Area in 2022 and Fortune's Best Workplaces in BioPharma in 2022.

Royalty Pharma

Deerfield

Red Abbey Venture Partners

Federated Kaufmann Fund

International BM Biomedicine Holdings AG

New Medical Technologies

Duke University

Sevin Rosen Funds

Mayfield Fund

Vulcan

Cytokinetics

CYTK Investors: Today we announced we will be presenting at the upcoming Oppenheimer & Co. Inc. investor conference on February 13, 2024. 

Today we recognize #WearRedDay to spread awareness for women's heart health. Cardiovascular disease is the leading cause of death for women, killing more women than all forms of cancer combined and impacting women of all ages. Yet, many women don’t know that heart disease is their number one killer, made even worse by the fact that certain heart diseases can be “silent” or not diagnosed. Together, by wearing red, we are showing our support for heart disease prevention and bringing attention to the importance of heart health. #HeartMonth #HeartDiseaseAwareness #OurHearts #GoRedForWomen

To celebrate #BlackHistoryMonth, we're honoring the rich tapestry of African American culture and heritage that has shaped our world. This month is not just about the past, it's a call to action for the present and future. Let's learn, engage and uplift one another as we continue to build a world that celebrates diversity.

Learn more about the significance of this annual observance: https://bit.ly/3gptsgl

February is #HeartMonth! Follow along as we talk about #HeartDisease and connect with the community. Throughout the month, we will also be hosting internal company events to raise awareness and learn from patients about the burden of living with heart disease. #HCM

Today we announced the recipients of our sixth annual Cytokinetics Communications Grant Program. We are proud to support advocacy organizations in their efforts to build awareness and community engagement. 

Learn more:

Maze Therapeutics is a biotechnology company focused on developing therapies for genetic diseases.

Maze Therapeutics

Cytori Therapeutics is a biotechnology company specializing in regenerative medicine and developing cell-based therapeutics.

Cytori Therapeutics

Assembly Biosciences is a biotechnology company focused on developing innovative treatments for hepatitis B virus and other viral infections.

Assembly Biosciences

Amylyx Pharmaceuticals is a biopharmaceutical company dedicated to developing therapies for neurodegenerative diseases.

Amylyx Pharmaceuticals

Orphazyme is a biopharmaceutical company focused on developing therapies for rare neurodegenerative diseases.

Orphazyme

MediciNova is a biopharmaceutical company engaged in developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs.

MediciNova

Spider Biotech is a biotechnology company focused on developing synthetic peptide therapeutics for innate immunity and antimicrobial defense.

Spider Biotech

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases affecting muscle performance.

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Cytokinetics, Incorporated

industry_trends_dossier

news_impact_assignment_basic

key_people

company_dossier

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

network

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

events

strategic_challenges

network_mapping

industry_trends

transactions_dossier

strategic_challenges_dossier

network_onboarding

company_summary

regulatory_analysis

industry_analysis

swot_dossier

competition_analysis

financial_legal_advisories

merger_acquisitions

swot_analysis

financial_analysis

news_advanced

purchaser_profile

news_impact_assignment_advanced

signals

news_processing_advanced

financial_statements

private_financials

funding_rounds_analysis

company_structure

crunchbase_trigger

crunchbase_profile

li_profile

translate_crunchbase_fundingrounds

peers

news_basic

valuation

customer_profile

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom
news impact assignment basic	general	Mar 5, 2024 1:25 AM	4d2acf7a
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 5, 2024 1:25 AM	5fda2fa9
company summary	general
news advanced	general
news impact assignment advanced	general
signals	general
news processing advanced	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	Mar 5, 2024 1:25 AM	f5f0cf97
translate crunchbase fundingrounds	general
peers	general
news basic	general	Mar 5, 2024 1:25 AM	30ee60d3
events	markdown
bundesanzeiger	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
swot analysis	company_analysis
financial analysis	company_analysis	Sep 30, 2024 7:56 PM	aa5ce469
funding rounds analysis	company_analysis
company structure	company_analysis
purchaser profile	merger_acquisitions
private financials	financials
customer profile	customers

COM:CYTOKINETICS

Cytokinetics, Incorporated

Last Close

55.50

07/11 21:00

Market Cap

6.30B

Beta: -

Volume Today

125

Avg: -